Kirchberger MC, Berking C, Eisenried A (2025)
Publication Type: Journal article
Publication year: 2025
Book Volume: 27
Article Number: e78247
DOI: 10.2196/78247
Background: Vitiligo significantly impairs quality of life. Topical ruxolitinib is a novel Janus kinase inhibitor approved for nonsegmental vitiligo, but real-world patient experiences, particularly regarding efficacy, side effects, and access challenges following approval, are not fully captured by clinical trials. Online patient forums like Reddit offer valuable insights into these aspects. Objective: This study analyzed discussions on the r/Vitiligo subreddit regarding topical ruxolitinib to understand real-world patient experiences, perceived treatment success, side effects, access barriers, and overall sentiment. Methods: We conducted a retrospective, cross-sectional infodemiology study of posts and comments mentioning ruxolitinib or Opzelura on r/Vitiligo between January 2022 and December 2024. After filtering and preprocessing, 2950 entries were analyzed. Computational linguistics (all-MiniLM-L6-v2), including sentence-transformer embeddings for semisupervised topic classification into therapy success, side effects, insurance and cost, and off-topic, were used. Valence Aware Dictionary and Sentiment Reasoner (−1 to +1) for sentiment analysis was assessed. Temporal trends were analyzed; model performance was validated manually against blinded manual annotation of 500 entries. Representative qualitative data were reviewed. Results: Discussions increased following regulatory approvals. Therapy success was the largest cluster (entries: 1765/2950, 59.83%; 95% CI 58.1 to 61.6) with positive sentiment (mean score 0.473, 95% CI 0.46 to 0.48), frequently describing facial repigmentation and adjunctive use with phototherapy. Users reported encouraging hair repigmentation within treated areas and success even on vitiligo spots present for over 20 years, while noting that areas like hands and feet were particularly treatment-resistant. The side effects cluster (entries: 558/2950, 18.91%; 95% CI 17.5 to 20.3) had negative sentiment (mean score −0.110, 95% CI −0.14 to 0.07), frequently mentioning application-site acne, fatigue, and panic attacks or anemia. The insurance and cost cluster (entries: 491/2950, 16.64%; 95% CI 15.3 to 18.0) had positive sentiment (mean score 0.349, 95% CI 0.31 to 0.39), dominated by discussions on high costs and access difficulties, alongside strategies like co-pay programs but also noting insurance denials. Manual model validation showed substantial agreement (accuracy 88.4%, 95% CI 86 to 91; F
APA:
Kirchberger, M.C., Berking, C., & Eisenried, A. (2025). Real-World Use of Topical Ruxolitinib in Vitiligo: Retrospective Cross-Sectional Mixed Methods Infodemiology Study of the r/Vitiligo Subreddit. Journal of Medical Internet Research, 27. https://doi.org/10.2196/78247
MLA:
Kirchberger, Michael Constantin, Carola Berking, and Andreas Eisenried. "Real-World Use of Topical Ruxolitinib in Vitiligo: Retrospective Cross-Sectional Mixed Methods Infodemiology Study of the r/Vitiligo Subreddit." Journal of Medical Internet Research 27 (2025).
BibTeX: Download